Mallinckrodt acquires Endo (2025)

Deal facts

Buyer: Mallinckrodt
Target: Endo
Deal value: Not disclosed
Announced: 1 August 2025
Status: Completed
Sector: Healthcare
Country: United States
Consideration: cash

Sources

SEC_EDGAR_8K

What we know

Weekly digest

Join Exit Mode Insider

Ten deal briefs a week, founder commentary, and the patterns worth paying attention to.

Join Exit Mode Insider, £12/mo

Deal timeline

1 update

1 Aug 2025CompletedClosed
Mallinckrodt completes acquisition of Endo
Item 2.01 Completion of Acquisition or Disposition of Assets. The information set forth in the Introduction of this Current Report on Form 8-K is incorporated by reference into this Item 2.01. Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. The information set forth in the Introduction and Item 2.01 of this Current Report on Form 8-K
Source

OpinionExit Mode editorial

We see a definitive shift in the healthcare consolidation landscape with the completed acquisition of Endo by Mallinckrodt. This transaction, announced on 1 August 2025, marks a significant going-private move for a major US player. The deal structure relies entirely on cash consideration, which signals a clear preference for certainty over complex equity swaps. For the SME founder reading this, the choice of cash as the sole consideration type removes the immediate volatility of public market fluctuations from the exit equation. It forces a binary outcome where the value is fixed at the point of agreement rather than left to the whims of future trading.

The cross-border nature of this deal, moving from the United States to an Irish buyer, introduces specific regulatory hurdles that cannot be ignored. While the target is US-based, the Irish domicile of the acquirer means the transaction likely required careful navigation of both US and EU competition authorities. In healthcare, where supply chain continuity and patent protection are paramount, the Competition and Markets Authority or the European Commission would have scrutinised the combined entity for potential anti-trust issues. The successful completion suggests that the parties secured the necessary regulatory clearance, a process that often dictates the final timeline and can impose strict behavioural remedies on the merged business.

We believe this deal serves as a potent reminder that the mechanics of the exit are just as critical as the price tag. The going-private status implies that the combined entity will no longer face the quarterly earnings pressure of public markets, allowing for longer-term strategic investments. However, this shift also means the new owners will demand immediate operational efficiency. The absence of a disclosed value in the public record does not diminish the strategic weight of the move. It highlights that in a sector defined by high R&D costs and strict regulation, liquidity and control are often the primary drivers for a successful exit.

Your immediate task this week is to audit your own change-of-control covenants with your current lenders and key suppliers. Many SME founders overlook how a sale can trigger default clauses or require third-party consents that can derail a deal even after a price is agreed. Identify every contract that requires written approval for a change in ownership and prepare a mitigation plan before you ever sign a letter of intent.

Editorial opinion. Not financial or legal advice.

Explore

Browse adjacent archives

Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.

More Healthcare deals More 2025 deals More going private deals More from Mallinckrodt All M&A deals

Similar deals

Other Healthcare M&A activity tracked by Exit Mode.

5 May 2026CompletedHealthcare

Merck to acquire Terns Pharmaceuticals, Inc.

Merck and Terns Pharmaceuticals, Inc. entered the Exit Mode archive.

Buyer: Merck
Target: Terns Pharmaceuticals, Inc.
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

27 April 2026CompletedHealthcare

BioMarin Pharmaceutical Inc. to acquire Amicus Therapeutics, Inc.

BioMarin Pharmaceutical Inc. and Amicus Therapeutics, Inc. entered the Exit Mode archive.

Buyer: BioMarin Pharmaceutical Inc.
Target: Amicus Therapeutics, Inc.
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

23 April 2026CompletedHealthcare

Servier to acquire Day One Biopharmaceuticals, Inc.

Servier and Day One Biopharmaceuticals, Inc. entered the Exit Mode archive.

Buyer: Servier
Target: Day One Biopharmaceuticals, Inc.
Deal value: USD 2,500,000,000
Deal type: going private

Read deal Healthcare deals going private deals United States deals

30 March 2026CompletedHealthcare

Aurinia Pharma U.S., Inc. to acquire Kezar Life Sciences, Inc.

Aurinia Pharma U.S., Inc. and Kezar Life Sciences, Inc. entered the Exit Mode archive.

Buyer: Aurinia Pharma U.S., Inc.
Target: Kezar Life Sciences, Inc.
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

23 March 2026CompletedHealthcare

Abbott to acquire Exact Sciences Corp

Abbott and Exact Sciences Corp entered the Exit Mode archive.

Buyer: Abbott
Target: Exact Sciences Corp
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

Buyer history

Mallinckrodt

See every published Exit Mode archive entry where this buyer appears.

View buyer profile

Methodology

How this page is built

Layer 1 facts come from source documents, Layer 2 turns those facts into a readable narrative, and Layer 3 only appears where the editorial team flags a founder-relevant deal.

Back to the archive

Mallinckrodt to acquire Endo

Deal facts

Join Exit Mode Insider

Deal timeline

Browse adjacent archives

Similar deals

Merck to acquire Terns Pharmaceuticals, Inc.

BioMarin Pharmaceutical Inc. to acquire Amicus Therapeutics, Inc.

Servier to acquire Day One Biopharmaceuticals, Inc.

Aurinia Pharma U.S., Inc. to acquire Kezar Life Sciences, Inc.

Abbott to acquire Exact Sciences Corp

Mallinckrodt

How this page is built